Top insider buys and sells disclosed for Monday
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Damora Therapeutics Inc (DMRA)
The Damora Therapeutics share price today is 18.660, view NASDAQ DMRA stock exchange data. Track the latest Damora Therapeutics share price with real-time updates on DMRA stock performance including market cap, day range, 52-week range and dividend yield. Access DMRA charts, earnings dates and analyst estimates to support your investment decisions.
18.660
+0.230(+1.25%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.840
18.885
52 wk Range
4.950
38.325
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.84018.885
52 wk Range
4.95038.325
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DMRA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
46.889
Upside
+151.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Galecto Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 4 Damora Therapeutics Inc For: 28 September- Investing.com
- Top insider buys and sells disclosed for Monday
- Investing.com
- Form 4 Damora Therapeutics Inc For: 28 September
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 46.889
(+151.28% Upside)
Earnings
Latest Release
10-08-2026
EPS / Forecast
-0.39 / -0.44
Revenue / Forecast
-- / --
Compare DMRA to Peers and Sector
Metrics to compare | DMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | −3.4x | −0.3x | |
PEG Ratio | −0.19 | 0.04 | 0.00 | |
Price/Book | 2.9x | 1.4x | 2.6x | |
Price / LTM Sales | - | 2.8x | 2.9x | |
Upside (Analyst Target) | 156.5% | 297.5% | 64.3% | |
Fair Value Upside | Unlock | 14.7% | 10.0% | Unlock |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Damora Therapeutics (DMRA) Share Price Today?
The Damora Therapeutics share price today is 18.660.
What is the current Damora Therapeutics (DMRA) share price and day range?
As of 15-10-2026, the Damora Therapeutics share price is 18.660, with a previous close of 18.430. The share price has ranged from 17.840 to 18.885 today, while the 52-week range spans from 4.950 to 38.325.
What Is the Damora Therapeutics Market Cap?
As of today, Damora Therapeutics market cap is 1.130B.
What Is the Damora Therapeutics (DMRA) Share Price Target?
The average 12-month share price target for Damora Therapeutics is 46.889, with a high estimate of 60 and a low estimate of 40. 10 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +151.28% Upside potential.
What Is Damora Therapeutics's Earnings Per Share (TTM)?
The Damora Therapeutics EPS (TTM) is -9.88.
When Is the Next Damora Therapeutics Earnings Date?
Damora Therapeutics will release its next earnings report on 30-10-2026.
From a Technical Analysis Perspective, Is DMRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Damora Therapeutics Trade On?
Damora Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Damora Therapeutics?
The stock symbol for Damora Therapeutics is "DMRA."
How Many Times Has Damora Therapeutics Stock Split?
Damora Therapeutics has split 1 times.
How Many Employees Does Damora Therapeutics Have?
Damora Therapeutics has 7 employees.
What Is the DMRA Premarket Price?
DMRA's last pre-market stock price is 18.790. The pre-market share volume is 20.000, and the stock has changed by 0.360, or 1.950%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.